Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS South Dakota Tepezza Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.03.93

    Lumvoa (veligrotug-vvze) and Tepezza (teprotumumab-trbw)

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.03.93 alerts

    Get alerted when Policy 05.03.93 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and prior authorization for Lumvoa (veligrotug-vvze) and Tepezza (teprotumumab-trbw) in members with thyroid eye disease. Coverage requires the applicable clinical criteria, documentation, specialist involvement, and benefit eligibility.

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyLumvoa (veligrotug-vvze) and Tepezza (teprotumumab-trbw)
    Policy CodePolicy 05.03.93
    Change TypeNo material change
    Effective DateSep 21, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation with the clinical activity score, applicable proptosis measurements, evidence of moderate-to-severe thyroid eye disease, and thyroid testing results.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Drugs covered by the policy
    18+

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Minimum member age for initial approval
    6 monthsInitial approval duration
    1 lifetime courseMaximum treatment course
    5 / 8Maximum infusions: Lumvoa / Tepezza
    CAS ≥3 / ≥4Active disease threshold: Lumvoa / Tepezza

    General Coverage Requirements

    Lumvoa initial therapy

    Lumvoa may be considered medically necessary when ALL of the following are met.

    Lumvoa initial approval

    • Age: Member is 18 years of age or older.
    • Thyroid eye disease and disease activity

      • ONE of the following disease pathways

        • Active disease: Member has thyroid eye disease with an active disease Clinical Activity Score (CAS) of ≥3.CAS ≥3
        • Chronic disease with proptosis: Member has moderate-to-severe chronic thyroid eye disease with proptosis ≥17 mm at the time of request and ≥3 mm above normal values for race and sex.Proptosis ≥17 mm and ≥3 mm above normal for race and sex
    • Disease severity: Member has moderate-to-severe thyroid eye disease.
    • Glucocorticoid therapy or qualifying exception

      • Member has experienced an inadequate response to glucocorticoids at a maximally tolerated dose.
      • Member has a documented intolerance, FDA-labeled contraindication, or hypersensitivity to glucocorticoids.
      • Member is currently receiving Lumvoa through insurance and is experiencing a positive therapeutic outcome; treatment obtained as samples or through a manufacturer's patient assistance program does not satisfy this condition.
    • Thyroid status: Member is euthyroid prior to initiating therapy.
    • Pregnancy status: Member is not currently pregnant and does not plan to become pregnant during treatment or within 6 months after the last treatment.
    • Prior therapy: Member has not received prior treatment with another insulin-like growth factor inhibitor, including Tepezza, for thyroid eye disease.

    Tepezza initial therapy

    Tepezza may be considered medically necessary when ALL of the following are met.

    Tepezza initial approval

    • Age: Member is 18 years of age or older.
    • Thyroid eye disease and disease activity

      • ONE of the following disease pathways

        • Active disease: Member has thyroid eye disease with an active disease Clinical Activity Score (CAS) of ≥4.CAS ≥4
        • Chronic disease with proptosis: Member has moderate-to-severe chronic thyroid eye disease with either a ≥3 mm increase in proptosis from baseline before the thyroid eye disease diagnosis or proptosis ≥3 mm above normal values for race and sex.

    Prior treatment with the other insulin-like growth factor inhibitor for thyroid eye disease precludes approval. A Lumvoa request is not approvable when the member has previously received Tepezza for TED, and a Tepezza request is not approvable when the member has previously received Lumvoa for TED.

    Pregnancy is an exclusion. The member must not be pregnant when treatment is initiated and must not plan to become pregnant during treatment or within 6 months after the last treatment.

    Billing Codes and Clinical Thresholds

    Tepezza HCPCS Code - DeletedHCPCS
    C9061Injection, teprotumumab-trbw, 10 mg (deleted 09-30-2020)
    Lumvoa HCPCS CodesHCPCS
    C9399Unclassified drugs/biologics (when specified as Lumvoa [veligrotug])
    Tepezza HCPCS CodeHCPCS
    J3241Injection, teprotumumab-trbw, 10 mg (effective 10-01-2020)
    Lumvoa HCPCS CodesHCPCS
    J3490Unclassified drugs (when specified as Lumvoa [veligrotug])
    J3590Unclassified biologics (when specified as Lumvoa [veligrotug])
    Lumvoa Active Disease Threshold
    Active thyroid eye diseaseClinical Activity Score (CAS) ≥3
    Applicable productLumvoa (veligrotug-vvze)
    Coverage pathwayActive disease pathway for thyroid eye disease
    Lumvoa Chronic TED Proptosis
    Proptosis at request≥17 mm
    Difference from normal≥3 mm above normal values for race and sex

    Prior Authorization and Submission Requirements

    Prior Authorization

    Submit prior authorization documentation

    Prior authorization is required. Submit supporting chart notes or medical records with the clinical activity score, applicable proptosis measurements, evidence of moderate-to-severe thyroid eye disease, and thyroid testing results.

    Prior Authorization

    Obtain thyroid eye disease specialist involvement

    The requested medication must be prescribed by or used in consultation with a specialist who treats thyroid eye disease.

    Step Therapy

    Document prior glucocorticoid therapy or exception

    The member must have experienced an inadequate response to glucocorticoids at a maximally tolerated dose, unless a qualifying exception is documented. An exception may include intolerance, an FDA-labeled contraindication, or hypersensitivity; members already receiving the requested product through insurance may qualify when experiencing a positive therapeutic outcome.

    Policy Background

    Lumvoa (veligrotug-vvze) and Tepezza (teprotumumab-trbw) are covered for the treatment of thyroid eye disease regardless of disease activity or duration when all applicable policy criteria are met. Coverage is subject to clinical eligibility, prior authorization, required documentation, specialist involvement, and benefit eligibility. The policy evaluates disease using drug-specific active disease thresholds or chronic proptosis criteria, along with moderate-to-severe disease findings. Initial approval is limited to 6 months and one course per lifetime, with up to 5 Lumvoa infusions or 8 Tepezza infusions.

    Clinical Definitions

    Clinical Activity Score (CAS)
    Pain behind the globePainful feeling behind the globe over the last 4 weeks
    Pain with eye movementPain with eye movement during the last 4 weeks
    Eyelid rednessRedness of the eyelids
    Conjunctival rednessRedness of the conjunctiva
    Eyelid swellingSwelling of the eyelids
    ChemosisEdema of the conjunctiva
    Swollen caruncleSwollen caruncle (flesh body at the medial angle of the eye)

    Drug-Specific Initial Approval

    Lumvoa initial approval

    Lumvoa may be considered medically necessary for the treatment of thyroid eye disease when ALL of the following criteria are met.

    • Age: Member is 18 years of age or older.
    • Disease activity or chronic proptosis pathway

      • Active disease: Member has a diagnosis of thyroid eye disease with active disease and a Clinical Activity Score (CAS) of ≥3.CAS ≥3
      • Moderate-to-severe chronic disease: Member has moderate-to-severe chronic thyroid eye disease with proptosis ≥17 mm at the time of request and proptosis ≥3 mm above normal values for race and sex.

    Required Prior Therapy

    StepRequirementQualifying exceptions
    1Use glucocorticoids at a maximally tolerated dose before the requested drug; the member must have an inadequate response.The requirement is waived for documented intolerance, an FDA-labeled contraindication, or hypersensitivity. A member already receiving the requested product through insurance may qualify with a positive therapeutic outcome. Samples and manufacturer patient assistance programs do not satisfy this condition.

    Infusion and Lifetime Course Limits

    Lumvoa Quantity Limit
    ProductLumvoa (veligrotug-vvze)
    Infusion limitUp to 5 infusions
    Lifetime limitOne course per lifetime
    Tepezza Quantity Limit
    ProductTepezza (teprotumumab-trbw)
    Infusion limitUp to 8 infusions
    Lifetime limitOne course per lifetime
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyLumvoa (veligrotug-vvze) and Tepezza (teprotumumab-trbw)
    Policy CodePolicy 05.03.93
    Change TypeNo material change
    Effective DateSep 21, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation with the clinical activity score, applicable proptosis measurements, evidence of moderate-to-severe thyroid eye disease, and thyroid testing results.
    SourceLink
    On This Page
    General Coverage RequirementsBilling Codes and Clinical ThresholdsPrior Authorization and Submission RequirementsPolicy BackgroundClinical DefinitionsDrug-Specific Initial ApprovalRequired Prior TherapyInfusion and Lifetime Course Limits
    Proptosis increase ≥3 mm from baseline or ≥3 mm above normal for race and sex
  1. Disease severity: Member has moderate-to-severe thyroid eye disease.
  2. Glucocorticoid therapy or qualifying exception

    • Member has experienced an inadequate response to glucocorticoids at a maximally tolerated dose.
    • Member has a documented intolerance, FDA-labeled contraindication, or hypersensitivity to glucocorticoids.
    • Member is currently receiving Tepezza through insurance and is experiencing a positive therapeutic outcome; treatment obtained as samples or through a manufacturer's patient assistance program does not satisfy this condition.
  3. Thyroid status: Member is euthyroid prior to initiating therapy.
  4. Pregnancy status: Member is not currently pregnant and does not plan to become pregnant during treatment or within 6 months after the last treatment.
  5. Prior therapy: Member has not received prior treatment with another insulin-like growth factor inhibitor, including Lumvoa, for thyroid eye disease.
  6. Disease pathway
    Moderate-to-severe chronic thyroid eye disease
    Tepezza Active Disease Threshold
    Active thyroid eye diseaseClinical Activity Score (CAS) ≥4
    Applicable productTepezza (teprotumumab-trbw)
    Coverage pathwayActive disease pathway for thyroid eye disease
    Tepezza Chronic TED Proptosis
    Increase from baseline≥3 mm from baseline before thyroid eye disease diagnosis
    Difference from normal≥3 mm above normal values for race and sex
    Disease pathwayModerate-to-severe chronic thyroid eye disease
    Moderate-to-Severe Disease: Lid Retraction
    Lid retraction≥2 mm
    Disease categoryModerate-to-severe thyroid eye disease
    Severity assessmentAt least one qualifying finding is required
    Moderate-to-Severe Disease: Exophthalmos
    Exophthalmos≥3 mm above normal for race and gender
    Disease categoryModerate-to-severe thyroid eye disease
    Severity assessmentAt least one qualifying finding is required
    • Samples and manufacturer patient assistance programs do not satisfy the current-therapy condition.
    Documentation Required

    Provide complete clinical documentation

    Submit supporting chart notes or medical records documenting the clinical activity score, proptosis testing when applicable, moderate-to-severe disease, and thyroid testing results.

    • Document the applicable disease activity or proptosis findings.
    • Include thyroid testing results.
    Documentation Required

    Document the prescriber’s specialist involvement

    Document that the requested medication is prescribed by or in consultation with a thyroid eye disease specialist. Acceptable specialists include an endocrinologist, ophthalmologist, oculoplastic surgeon, or neuroophthalmologist.

    Denial Risk

    Meet all initial approval criteria

    Coverage may be denied if the member is younger than 18, does not meet the drug-specific thyroid eye disease activity or proptosis criteria, does not have moderate-to-severe disease, lacks an inadequate glucocorticoid response or qualifying exception, is not euthyroid, is pregnant or plans pregnancy during treatment or within 6 months after the last treatment, or previously received the other insulin-like growth factor inhibitor for thyroid eye disease.

    Denial Risk

    Stay within course and infusion limits

    Requests exceeding the approved six-month period or the single lifetime course limit may be denied. Lumvoa is limited to up to five infusions per lifetime, and Tepezza is limited to up to eight infusions per lifetime.

    • Lumvoa: one course per lifetime, up to 5 infusions.
    • Tepezza: one course per lifetime, up to 8 infusions.
    Denial Risk

    Confirm required specialist involvement

    The request may be denied or require correction when the medication is not prescribed by or in consultation with a specialist in thyroid eye disease.

    Moderate-to-Severe Thyroid Eye Disease
    Lid retraction≥2 mm
    Soft-tissue involvementModerate or severe soft-tissue involvement
    Exophthalmos≥3 mm above normal for race and gender
    DiplopiaInconstant or constant diplopia
    Sight-Threatening Disease
    Qualifying conditionDysthyroid optic neuropathy (DON)
    Qualifying conditionCorneal breakdown
    DefinitionSight-threatening disease is present when at least one qualifying condition is present
    Proptosis ≥17 mm and ≥3 mm above normal for race and sex
  7. Disease severity: Member has moderate-to-severe thyroid eye disease.
  8. Glucocorticoid therapy or qualifying exception

    • Member has experienced an inadequate response to glucocorticoids at a maximally tolerated dose.
    • Member has a documented intolerance, FDA-labeled contraindication, or hypersensitivity to glucocorticoids.
    • Member is currently receiving Lumvoa through insurance and is experiencing a positive therapeutic outcome; treatment obtained as samples or through a manufacturer's patient assistance program does not satisfy this condition.
  9. Thyroid status: Member is euthyroid prior to initiating therapy.
  10. Pregnancy status: Member is not currently pregnant and does not plan to become pregnant during treatment or within 6 months of the last treatment.
  11. Prior insulin-like growth factor inhibitor therapy: Member has not received prior treatment with another insulin-like growth factor inhibitor, including Tepezza, for the treatment of thyroid eye disease.
  12. Tepezza initial approval

    Tepezza may be considered medically necessary for the treatment of thyroid eye disease when ALL of the following criteria are met.

    • Age: Member is 18 years of age or older.
    • Disease activity or chronic proptosis pathway

      • Active disease: Member has a diagnosis of thyroid eye disease with active disease and a Clinical Activity Score (CAS) of ≥4.CAS ≥4
      • Moderate-to-severe chronic disease: Member has moderate-to-severe chronic thyroid eye disease with either a ≥3 mm increase in proptosis from baseline before the thyroid eye disease diagnosis or proptosis ≥3 mm above normal values for race and sex.Proptosis increase ≥3 mm from baseline or ≥3 mm above normal for race and sex
    • Disease severity: Member has moderate-to-severe thyroid eye disease.
    • Glucocorticoid therapy or qualifying exception

      • Member has experienced an inadequate response to glucocorticoids at a maximally tolerated dose.
      • Member has a documented intolerance, FDA-labeled contraindication, or hypersensitivity to glucocorticoids.
      • Member is currently receiving Tepezza through insurance and is experiencing a positive therapeutic outcome; treatment obtained as samples or through a manufacturer's patient assistance program does not satisfy this condition.
    • Thyroid status: Member is euthyroid prior to initiating therapy.
    • Pregnancy status: Member is not currently pregnant and does not plan to become pregnant during treatment or within 6 months of the last treatment.
    • Prior insulin-like growth factor inhibitor therapy: Member has not received prior treatment with another insulin-like growth factor inhibitor, including Lumvoa, for the treatment of thyroid eye disease.